focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.37
Bid: 2.21
Ask: 2.43
Change: 0.075 (3.27%)
Spread: 0.22 (9.955%)
Open: 2.35
High: 2.37
Low: 2.35
Prev. Close: 2.295
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss

Mon, 25th Mar 2024 10:55

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 36% at 2.61 pence, 12-month range 0.82p-3.80p. The drug discovery and development company updates on Incanthera PLC's commercial skincare deal, announced in December 2023, with Marionnaud, part of the AS Watson Group. Says the first order from Marionnaud has now doubled to 50,000 units due to the strong demand anticipated by Marionnaud's management. The first order, on track to be delivered during the second quarter of 2024, will generate around GBP2 million in revenue for Incanthera, ImmuPharma said. ImmunPharma holds an 11% stake in Incanthera. ImmuPharma Chief Operating Officer Tim Franklin comments: "As a major shareholder in Incanthera, we are delighted with this further progress and in particular Incanthera's revenue momentum and move into profitability. This highlights the strong financial asset we have in Incanthera and the enormous opportunities within the company's revolutionary skincare range and its partnership with Marionnaud."

----------

Caspian Sunrise PLC, up 26% at 3.28p, 12-month range 2.20p-7.49p. The Kazakhstan-focused oil and gas exploration and production company said it was mulling the sale of all or part of the BNG contract area's shallow structures at "indicative prices potentially significantly greater than its current carrying value". Says any deal would likely require shareholder approval due to its size of the transaction value relative to the group. "We believe this heightened level of corporate interest in BNG's producing shallow structures is in part the result of the changes last year to the Kazakh oil trading regulations, which now require the production of oil to obtain a trading licence, and the relative scarcity of producing fields with full production licences. The sharp reduction in the discount for international sales referred to below may also have had an effect," the company says. Caspian Sunrise says no binding agreements have been entered into and there is no certainty that discussions will lead to a firm offer or that the board would put an offer before shareholders.

----------

AIM - LOSERS

----------

Aeorema Communications PLC, down 19% at 60.5p, 12-month range 55.00p-119.40p. In the six months that ended December 31, swings to pretax loss of GBP243,534 from a profit of GBP326,021 a year earlier. Revenue falls to GBP6.6 million from GBP7.1 million, while administrative expenses rise to GBP1.7 million from GBP1.2 million. Expects full-year revenue of no less than GBP19 million compared to GBP20.2 million in the financial year that ended June 30, 2023. Chair Mike Hale comments: "With a focus on adaptability and forward planning, Aeorema is well positioned for the future and is confident in its ability to deliver sustainable growth and value creation over the long term. We also expect to reaffirm our commitment to shareholders by maintaining our dividend policy. While this half year's financial performance reflects the impact of project timing, we are encouraged by the underlying strength of our business and our pipeline. Our focus remains steadfast on delivering creative brilliance for our clients on a global scale, and sustained growth and value to our shareholders."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
12 Apr 2023 14:13

ImmuPharma progresses P140 clinical programme with FDA

(Sharecast News) - Drug discovery and development company ImmuPharma announced positive progress in its late-stage P140 clinical programme on Tuesday, for patients with chronic idiopathic demyelinating polyneuropathy (CIDP), a rare neurological disease with high medical need.

Read more
12 Apr 2023 11:27

IN BRIEF: ImmuPharma shares up as FDA meeting for new drug confirmed

ImmuPharma PLC - London-based drug discovery and development company - Gets confirmation of a pre-investigational new drug meeting with the US Food & Drug Administration, which will take place on May 16. It concerns the phase 2/3 adaptive trial study protocol for P140 in chronic idiopathic demyelinating polyneuropathy. Says the CIDP market is expected to reach global sales of USD2.7 billion by 2029. CIDP is a rare acquired autoimmune disorder of peripheral nerve affecting about 50,000 individuals across the US and Europe.

Read more
12 Apr 2023 10:37

AIM WINNERS & LOSERS: System1 rises after upturn in second half

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
12 Apr 2023 08:49

LONDON MARKET OPEN: Stocks looking for direction before US inflation

(Alliance News) - Stock prices in London opened mixed on Wednesday, as caution prevailed ahead of a US inflation reading and minutes from the Federal Reserve's March meeting.

Read more
27 Mar 2023 12:05

LONDON MARKET MIDDAY: Bank stocks get boost as SVB assets bought

(Alliance News) - Stock prices in London were higher at midday on Monday, as investor sentiment was lifted by the news that a US bank will buy more USD70 billion dollars of Silicon Valley Bank assets.

Read more
27 Mar 2023 10:51

AIM WINNERS & LOSERS: ScotGold drops two-thirds as gold grade declines

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
27 Mar 2023 10:32

ImmuPharma submits phase 2/3 protocol to US FDA for Lupuzor treatment

(Alliance News) - ImmuPharma PLC on Monday said it submitted a phase 2/3 clinical trial protocol to the US Food & Drug Administration testing the Lupuzor treatment for lupus patients.

Read more
6 Mar 2023 11:22

ImmuPharma signs 12-month deal with Orano for use of peptide tech

(Alliance News) - ImmuPharma PLC on Monday said it has signed an initial collaboration agreement with Orano SA for its peptide technology.

Read more
6 Feb 2023 11:37

ImmuPharma agrees study design with Avion for lupus programme Lupuzor

(Alliance News) - ImmuPharma PLC on Monday confirmed alongside its partner Avion Pharmaceuticals that a phase 2/3 adaptive trial will be the best design for the next clinical study of Lupuzor in systemic lupus erythematosus patients.

Read more
22 Dec 2022 21:09

TRADING UPDATES: Ground Rents Income Fund's portfolio value drops

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
11 Nov 2022 19:56

TRADING UPDATES: Driver records loss; Synectics sells business unit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
11 Nov 2022 13:04

ImmuPharma upbeat after meeting with US partner Avion

(Sharecast News) - Drug discovery and development specialist ImmuPharma updated the market on a recent meeting in Atlanta with its United States partner Avion Pharmaceuticals on Friday, for strategic discussions around its 'Lupuzor' clinical programme.

Read more
6 Oct 2022 20:10

TRADING UPDATES: ImmuPharma loss narrows; MetalNRG loss widens

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
23 Sep 2022 15:56

UK earnings, trading statements calendar - next 7 days

Monday 26 September 
Atome Energy PLCHalf Year Results
Chapel Down Group PLCHalf Year Results
Concurrent Technologies PLCHalf Year Results
CPPGroup PLCHalf Year Results
Devolver Digital IncHalf Year Results
Dillistone Group PLCHalf Year Results
Finsbury Food Group PLCFull Year Results
Frenkel Topping Group PLCHalf Year Results
Immotion Group PLCHalf Year Results
Likewise Group PLCHalf Year Results
Microlise Group PLCHalf Year Results
Next Fifteen Communications PLCHalf Year Results
SpaceandPeople PLCHalf Year Results
XLMedia PLCHalf Year Results
Xpediator PLCHalf Year Results
Tuesday 27 September 
AG Barr PLCHalf Year Results
Animalcare Group PLCHalf Year Results
Billington Holdings PLCHalf Year Results
Boku IncHalf Year Results
Card Factory PLCHalf Year Results
Close Brothers Group PLCFull Year Results
Diaceutics PLCHalf Year Results
Digitalbox PLCHalf Year Results
ECSC Group PLCHalf Year Results
Ergomed PLCHalf Year Results
Ferguson PLCFull Year Results
FireAngel Safety Technology Group PLCHalf Year Results
GENinCode PLCHalf Year Results
Gresham House Energy Storage Fund PLCHalf Year Results
K3 Capital Group PLCFull Year Results
Instem PLCHalf Year Results
LifeSafe Holdings PLCHalf Year Results
Medica Group PLCHalf Year Results
Mission Group PLCHalf Year Results
Mortgage Advice Bureau PLCHalf Year Results
NAHL Group  PLCHalf Year Results
Origin Enterprises PLCFull Year Results
United Utilities Group PLCTrading Statement
Personal Group Holdings PLCHalf Year Results
S&U PLCHalf Year Results
Saga PLCHalf Year Results
Serica Energy PLCHalf Year Results
SSP Group PLCTrading Statement
tinyBuild IncHalf Year Results
Transense Technologies PLCFull Year Results
Yu Group PLCHalf Year Results
Wednesday 28 September 
1Spatial PLCHalf Year Results
AVI Japan Opportunity Trust PLCHalf Year Results
Avingtrans PLCFull Year Results
Blancco Technology Group PLCFull Year Results
boohoo Group PLCHalf Year Results
DP Poland PLCHalf Year Results
Everyman Media Group PLCHalf Year Results
Octopus Renewables Infrastructure Trust PLCHalf Year Results
Shepherd Neame LtdFull Year Results
Skillcast Group PLCHalf Year Results
SolGold PLCFull Year Results
Thursday 29 September 
Allergy Therapeutics PLCFull Year Results
Angle PLCHalf Year Results
Avation PLCFull Year Results
Bango PLCHalf Year Results
Cap-XX LtdHalf Year Results
Celadon Pharmaceuticals PLCHalf Year Results
Crestchic PLCHalf Year Results
Directa Plus PLCTrading Statement
McBride PLCFull Year Results
NAHL Group PLCHalf Year Results
Next PLCHalf Year Results
Novacyt SAHalf Year Results
Physiomics PLCFull Year Results
Synairgen PLCHalf Year Results
XLMedia PLCHalf Year Results
Friday 30 September 
abrdn Property Income Trust LtdHalf Year Results
Bluefield Solar Income Fund LtdFull Year Results
Cineworld Group PLCHalf Year Results
CMO Group PLCHalf Year Results
Dignity PLCHalf Year Results
DP Eurasia NVHalf Year Results
DX Group PLCFull Year Results
Glantus Holdings PLCHalf Year Results
HealthBeacon PLCHalf Year Results
ImmuPharma PLCHalf Year Results
Iofina PLCHalf Year Results
Oncimmune Holdings PLCHalf Year Results
Pennon Group PLCTrading Statement
Quarto Group IncHalf Year Results
Strip Tinning Holdings PLCHalf Year Results
Trellus Health PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
14 Sep 2022 13:51

ImmuPharma's US partner receives FDA response on Lupuzor

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Wednesday that its US partner for 'Lupuzor', Avion Pharmaceuticals, has received a written response from the Food and Drug Administration (FDA).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.